IDH1 and glioma: However, patients with IDH1/2 wt gliomas and low Ki-67 expression survived longer than those with IDH1/2 mut gliomas and high Ki-67 expression (Median OS =1234 vs. 566 days), which contradicts the findings in Figure 1A.